Diabetes Mellitus, Type 2
Conditions
Keywords
pharmacodynamics, first time in human, pharmacokinetics
Brief summary
The purpose of this study is to look at the safety and tolerability of increasing single doses of GSK2330672 in healthy volunteers.
Detailed description
This is a single blind, randomized, placebo-controlled, dose escalating, crossover, first time in human study to examine safety, tolerability, pharmacokinetic and pharmacodynamic parameters of GSK233672. Single blind indicates that the subjects and investigator are blinded to treatment but the GSK study team could be unblinded for ongoing review of interim safety data required for dose escalation. Subjects will participate in 4 dosing periods. Subjects will enter the clinic prior to dinner time on the evening of Day -1 of each period and will remain in residence through the morning of Day 3. Barring any safety or tolerability concerns, subjects will be released at this time provided they have had at least 1 bowel movement after dosing in the clinic. Subjects will return for their next scheduled dosing period. This process will be repeated for each dosing period. Subjects will return approximately 1 week after check out from their last dosing period for a follow up visit. Subjects will receive standardized meals meeting specific criteria starting with dinner on Day-1 and continuing through Day 1. Standard meals will be provided for the remainder of their stay in the clinic. After an overnight fast, subjects will take their study drug on the morning of Day 1. Dosing will be followed by breakfast and frequent blood sampling to assess pharmacokinetic and pharmacodynamic parameters. Scheduled assessments of heart rate, blood pressure, respiratory rate, ECGs, and clinical laboratories will be obtained to monitor subject safety. Subjects will be connected to cardiac telemetry monitors and will periodically undergo spirometry testing of ventilation parameters. Stool form and frequency of bowel movements will be recorded. All fecal samples will be collected from participants for 48 hours after dosing of study drug, or until they have had at least 1 bowel movement after dosing, whichever occurs first.
Interventions
DRUGplacebo
Vehicle used to dilute the powder for oral administration.
DRUG0.1 mg GSK2330672
GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
DRUG0.3 mg GSK2330672
GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
DRUG1 mg GSK2330672
GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
DRUG3 mg GSK2330672
GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
DRUG10 mg GSK2330672
GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
DRUG30 mg GSK2330672
GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
DRUG60 mg GSK2330672
GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* healthy volunteer * 18-60 yrs of age * for subjects age 50 and above: negative fecal occult blood test within 3 months prior to expected start of dosing, and normal results from sigmoidoscopy or colonoscopy within 5 yrs prior to dosing. * if female, must be of non-childbearing potential
Exclusion criteria
* pregnant or breastfeeding females * positive HIV * positive Hep B, or Hep C within 3 months of screening * positive drugs of abuse screening * triglycerides \> 250 mg/dL * current or chronic history of liver disease * any gastrointestinal or gastrointestinal related conditions that could affect fat or bile acid reabsorption * pancreatitis * colon cancer or 1st degree relative who has had colon cancer * abnormal lung function tests * inability to perform lung function tests * unwilling to abstain from smoking, alcohol, caffeine, illicit drugs as directed by the site staff * exposure to more than 4 new chemical entities in the 12 months prior to the first dosing day. * where participation in the study would results in donation of more than approximately 550mL of blood in a 56-day period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ECGs relative to placebo | 1, 2, 4, 8, 12, 24, 48 hours | frequency of clinically significant changes in 12-lead ECG parameters relative to placebo |
| Changes in clinical lab results | 24 hours | Changes in clinical chemistry, hematology, urinalysis results relative to placebo |
| Change in vital signs | 1, 2, 4, 8, 12, 24, 48 hours | frequency and absolute value change in heart rate, blood pressure, respiration rate relative to placebo |
| lung function tests | 1, 3, 8, 24 hours | Measure changes in FEV, FVC, FEF 25-75%, PEFR relative to placebo |
| Adverse events relative to placebo | 48 hour monitoring | Frequency and severity of adverse events relative to placebo |
Secondary
| Measure | Time frame |
|---|---|
| Measurement of the maximum concentration (Cmax) for study drug | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours |
| Measurement of the apparent volume of distribution (V/F) of the study drug | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours |
| Measurement of the time to achieve maximum concentration (tmax) for study drug | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours |
| Measurement of area under the curve (AUC) for study drug | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours |
| Measurement of half life (t 1/2) of study drug | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours |
| Measurement of apparent clearance (CL/F) of the study drug | 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours |
Countries
United States
Outcome results
None listed